All Posts: Lombardi Stories
-
Surgeon and Basic Scientists Partner to Develop New Way to Suss Out Early Problems in Liver Transplantation
A unique collaboration between basic scientists at Georgetown Lombardi and a transplant surgeon at MedStar Health could change how and when problems are identified with liver transplants, leading to expedited treatment and significantly reducing the need for additional testing.
Category: Lombardi Stories
-
Georgetown Global Health and Cancer Researchers Tackle Public Health Challenge in Eswatini
A collaboration between researchers at Georgetown’s Lombardi Comprehensive Cancer Center and a Georgetown global health team in Eswatini aims to address a significant public health challenge: preventing cervical cancer.
Category: Lombardi Stories
-
At 36th Annual Lombardi Gala, Friends Help Push Boundaries
A community of nearly 500 new and longtime friends donned gowns and black ties for the 36th annual Lombardi Gala, the largest continuous fundraising event for Georgetown’s Lombardi Comprehensive Cancer Center.
Category: Lombardi Stories
-
Psychosocial Oncology Program Promotes Cura Personalis in Cancer Care
As director of the psychosocial oncology program at Georgetown Lombardi, Kimberly M. Davis, PhD, supports the psychological needs of cancer patients, while also training future independent clinical researchers in the field.
Category: Lombardi Stories
-
Two Undergraduates Working in Georgetown Lombardi Labs Receive Goldwater Scholarships
Dua Mobin (C’25), who works in the Braselmann Lab, and Morgan Rice (C’25), who works in the Riggins Lab, were named 2024 Goldwater Scholars. One of the most prestigious awards for undergraduates in science, technology, engineering and math, the Goldwater Scholarship is given to support and cultivate the next generation of scientists, researchers and engineers.
Category: Lombardi Stories
-
Ralph Lauren Center Marks Its First Year at Georgetown
Nearly one year after the opening of the Ralph Lauren Center for Cancer Prevention, Ralph Lauren leaders toured the center and received an update on its accomplishments from center leaders and staff.
Category: Lombardi Stories
-
Hackensack Meridian John Theurer Cancer Center Treats its First Patient in Innovative Cell Therapy Clinical Trial
Researchers at Hackensack Meridian John Theurer Cancer Center — part of the National Cancer Institute-designated Lombardi Comprehensive Cancer Center at Georgetown University —treated its first patient at the Center in a cutting-edge phase I clinical trial of LYL845, a novel cellular therapy under evaluation for advanced melanoma and other select solid tumors. A type of tumor-infiltrating lymphocyte (TIL) therapy, LYL845 is custom-made from a patient’s cells and designed to help the immune system find and kill cancer cells.
Category: Lombardi Stories
-
Could a Georgetown Lab Finding Lead to New Treatment in Pancreatic Cancer?
For the first time, new research by Georgetown scientists shows potential to make immunotherapy effective in pancreatic cancer by combining it with a drug that makes cancer cells more responsive to immunotherapy. The research is now in a phase 2 clinical trial being tested in human patients.
Category: Lombardi Stories
-
John Theurer Cancer Center Physician Co-Authors Clinical Research on Innovative Oral Leukemia Therapy
Researchers at Hackensack Meridian’s John Theurer Cancer Center are part of a published Phase 3 study reporting on the equivalent safety and effectiveness in the oral treatment of blood cancers, such as myelodysplastic syndrome and/or chronic myelomonocytic leukemia, to its previously inpatient, intravenous treatment counterparts. John Theurer Cancer Center is part of the NCI-designated Lombardi Comprehensive Cancer Center at Georgetown University.
Category: Lombardi Stories
-
John Theurer Cancer Center Physician Co-Authors Clinical Research on mRNA Vaccine Intervention Benefits in High-Risk Melanoma
Researchers at Hackensack University Medical Center’s John Theurer Cancer Center (JTCC), a part of the NCI-designated Lombardi Comprehensive Cancer Center at Georgetown University, reported on a novel mRNA vaccine’s delivering improved survival rates in Stage IIIB and IV (metastatic) skin cancer, as part of an ongoing joint-study.
Category: Lombardi Stories